CNTA — Centessa Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $6.19bn
- $6.03bn
- $15.00m
Brief: Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering Of American Depositary Shares
Brief: Centessa Pharmaceuticals PLC Files For Mixed Shelf Size Not Disclosed - SEC Filing
Centessa Pharma drops on $150 mln share offering launch
U.S. STOCKS ON THE MOVE-Arrowhead Pharma, Boeing, Centessa Pharma
Centessa Pharma rises on early-stage data for sleep disorder drug
Brief: Centessa Pharmaceuticals Announces Pricing Of $100 Mln Public Offering Of American Depositary Shares
Brief: Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering Of American Depositary Shares
Brief: Centessa Pharmaceuticals Announces Additions To Senior Leadership Team
Brief: Centessa Pharmaceuticals Announces Dosing In PRESent-2 Study Evaluating SerpinPC
Brief: Centessa Pharmaceuticals Announces Dosing Of First Subject In Registrational Present-2 Study Evaluating Serpinpc For The Treatment Of Hemophilia B Without Inhibitors
Centessa Pharma rises on FDA's 'fast-track' tag for bleeding disorder therapy
Brief: Centessa Pharmaceuticals Receives Fast Track Designation From The U.S. FDA For Serpinpc For Hemophilia B
Brief: Centessa Pharmaceuticals Reports Q1 2023 Financial Results And Business Highlights
Brief: Centessa Pharmaceuticals Reports Financial Results For The Fourth Quarter And Full-Year 2022
Brief: Centessa Pharmaceuticals PLC Entered Into A Sales Agreement With Svb Securities Llc
Centessa Pharma rises on FDA nod to begin human trials for tumor therapy
Brief: Centessa Pharmaceuticals Announces FDA Clearance Of Ind Application For Phase 1/2A Clinical Trial Of Lb101, First Lockbody® Candidate, For Solid Tumors
Brief: Centessa Pharmaceuticals Announces Additional 18-Months Of Continued Treatment Data From Open-Label Extension (Ole) Of Phase 2A Study Of Serpinpc For Hemophilia
Brief: Centessa Pharmaceuticals Reports Q3 Financial Results